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Background: Previously, we reported on the unexpected development of distant metastases in the subcutaneous
rat pancreas CA20948 tumor model after 4.5 weeks of treatment with RAD001-only or in combination with
[177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) (Cancer Res. 73:12-8, 2013). Moreover, the combination therapy was
less effective compared to 177Lu-DOTATATE-only. In the current study, we address the following questions: (1) Why
was the combination therapy less effective? Is 177Lu-DOTATATE tumor uptake affected by pretreatment with
RAD001? (2) Could sudden cessation of RAD001 therapy cause the development of distant metastases? (3) Is
177Lu-DOTATATE an effective treatment option for these metastases?
Methods: Lewis rats (HanHsd or SsNHsd substrain with a slight difference in immune response) bearing
subcutaneous CA20948 tumors were treated with either 125 or 275 MBq 177Lu-DOTATATE, RAD001, or their
combination. RAD001 was given twice a week for 4.5 or 12 weeks, whereas 177Lu-DOTATATE was given as a single
injection. When combined, RAD001 was started either 3 days prior to or 3 days post administration of
177Lu-DOTATATE. SPECT/CT was performed to quantify 177Lu-DOTATATE tumor uptake. Where indicated, primary
tumors were surgically removed when tumor size is >6,000 mm3 to enable monitoring for possible metastasis. If
metastases were suspected, an 111In-DTPA-octreotide SPECT/CT scan was performed. Seven rats with metastases
were treated with 400 MBq 177Lu-DOTATATE.
Results: Lu-DOTATATE tumor uptake was not significantly affected by RAD001 pretreatment. The occurrence of
metastases after RAD001 treatment was not dose dependent in the dose range tested, nor was it related to the
duration of RAD001 treatment. In the experiment in which the LEW/SsNsd substrain was used, only 12.5% of
RAD001-treated rats showed complete response (CR), compared to 50% tumor regression in the control group.
Re-treatment with a high dose of 177Lu-DOTATATE resulted in CR in only two out of seven animals.
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Conclusion: Less effective anti-tumor effects after the combination of RAD001 + 177Lu-DOTATATE could not be
explained by reduced 177Lu-DOTATATE tumor uptake after RAD001. Our current data support RAD001-induced
immune suppression as the reason for this observation. No evidence was found that cessation of RAD001 treatment
caused development of metastases. Metastases appeared to be less sensitive to 177Lu-DOTATATE treatment than
primary tumors.
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Neuroendocrine tumors (NETs) consist of a heteroge-
neous group of neoplasms originating from cells charac-
terized by the synthesis and release of amines/peptides
[1]. Since 1973, the incidence of NETs has been increas-
ing, in which genetic factors might play a role [2] and in
addition improved diagnostics contributed to a higher
registered incidence of NETs [1]. Because NETs are
slowly proliferating tumors, the prevalence of NETs is
much higher than the incidence, resulting in a relatively
high percentage of NET patients in the population of
cancer patients [3]. In >50% of the patients, NETs are
diagnosed at a relatively late stage, often with metastatic
spread [2], which leaves little chance for curative surgery.
As a consequence of the slow proliferation rate, most
NETs are relatively resistant to chemotherapeutics.
Most NETs are characterized by overexpression of
somatostatin receptors, mainly subtype 2 (sst2). Target-
ing these receptors by administration of somatostatin
analogs radiolabeled with, e.g., beta particle-emitting
radionuclides, such as 177Lu or 90Y, allows peptide re-
ceptor radionuclide therapy (PRRT) of NET patients.
This therapeutic approach is being performed since
more than 10 years and has proven to be an effective
treatment option in patients with inoperable disease.
Therapeutic responses result in a significantly longer
overall survival time compared to other treatments
such as chemotherapy or external beam radiation ther-
apy [4-6]. PRRT also improves patient's self-assessed
quality of life [7]. Although PRRT is a successful ther-
apy, complete remissions (CR) in patients with metas-
tasized disease are still rare, so there is an urgent need
for improvement.
The combination of PRRT with the mammalian target
of rapamycin (mTOR) inhibitor everolimus or RAD001
could be promising in this respect. Everolimus (RAD001)
has recently received FDA approval for the treatment of
pancreatic NETs. RAD001 has been reported to show
anti-tumor and anti-angiogenic activity both in vitro as
well as in vivo, since both tumor proliferation and
tumor angiogenesis are regulated by mTOR [8]. The
clinical RADIANT III trial, a randomized, double-blind,placebo-controlled, multicenter phase III trial in pan-
creatic neuroendocrine tumor (PNET) patients, showed
a median progression-free survival of 11 months after
daily administration of 10 mg RAD001 plus best sup-
portive care versus 4.6 months in the placebo group [2].
Since it was shown that RAD001 may act as radiosensi-
tizer in various tumor models [9], RAD001 and PRRT
could have a synergistic effect. Antitumor efficacies of
RAD001 treatment schedules in the CA20948 tumor
model have been reported before by Boulay et al. [10].
In this study, comparable anti-tumor effects were shown
for twice weekly and daily RAD001 administration.
We have performed a combination study of the two
treatments in the sst2-expressing CA20948 tumor-
bearing rat model on which we recently reported the
first data [11]. In this study, we compared either 177Lu-
DOTATATE, RAD001, or their combination for treat-
ment of tumor-bearing rats. RAD001 was administered
orally twice a week for 4.5 weeks, and a suboptimal dose
of 177Lu-DOTATATE (leaving room for additional effect
of RAD001) was given once. Unexpectedly, we observed
that the majority (77%) of rats treated with RAD001
(single treatment or combined with PRRT) developed
metastases. We have used this subcutaneous CA20948
tumor model in many PRRT studies for more than
10 years, and metastases never occurred before. We
have hypothesized that a rebound effect after stopping
the RAD001 treatment after 4.5 weeks initiated a metasta-
sizing process. Furthermore, we observed that rats treated
with the combination of RAD001 and 177Lu-DOTATATE
showed less impressive anti-tumor effects compared to
those treated with 177Lu-DOTATATE-only.
In the current studies, we performed additional in vivo
experiments in the same rat model and obtained add-
itional results from the previous studies. To find an
explanation for the lower therapeutic effect of the
combination vs. single 177Lu-DOTATATE therapy, 177Lu-
DOTATATE tumor uptake was quantified in tumors with
and without RAD001 pretreatment. Moreover, in LEW/
SsNsd rats, we studied the effects of longer, i.e., 12 instead
of 4.5 weeks, RAD001 treatment on the potential induc-
tion of metastasis.
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Tumor cell lines
The rat sst2-expressing pancreatic tumor CA20948 cell
line [12] was cultured in Dulbecco's modified Eagle's
medium (DMEM, Gibco, Invitrogen Corp., Breda, the
Netherlands) supplemented with 10% heat-inactivated
fetal bovine serum.
Animals and tumor model
The animal ethics committee of our institution has approved
all experiments. Male Lewis rats (250 to 300 g) were
obtained from Harlan (Heerlen, the Netherlands). We
used LEW/HanHsd Lewis rats, and where indicated,
we also included rats from the LEW/SsNHsd substrain.
In the LEW/SsNHsd substrain, the immune system shows
an enhanced CD4+ and CD8+ T cell (auto)-immune
response [13-17]. This autoimmunity is linked to an
increased tumor immunity [18,19]. One week after
arrival, rats were inoculated subcutaneously with 107
CA20948 cells in 0.5 ml HBSS. For all experiments,
animals were randomized into matching treatment
groups with regard to tumor size at the start of treat-
ment. A person blinded for the treatment measured
tumor size using a calliper and weighed the rats three
times a week. Tumor volume was calculated using the
formula: 0.4 × length × weight × height. Tumor response
was defined as follows: partial response (PR) as >50%
reduction of tumor volume and complete response
(CR) as 100% reduction of tumor volume. Tumors were
allowed to develop until a maximum of 4 to 6 cm3 and
were surgically removed where indicated. Rats were eutha-
nized when >10% loss of body weight (BW) was registered.
Anesthesia
2.5% Isoflurane/O2 gas anesthesia was used at 0.5 ml/min
during tumor cell inoculation, administration of 177Lu-
DOTATATE, scanning, or surgery.
Surgical procedure to remove the primary tumor
When primary tumors were >4 to 6 cm3, surgical tumor
resection was performed where indicated. During surgery,
a heating pat was used to maintain body temperature.
Routine shaving and disinfecting of the skin was per-
formed. The tumor including the tumor capsule was care-
fully dissected from the surrounding tissue. After tumor
resection, the skin was closed using individual sutures
(vicryl 3/0).
RAD001
RAD001 and its placebo, kindly provided by Novartis
Pharmaceuticals, Basel, Switzerland, were used for study
1 and prepared according to the manufacturer's protocol.
For the next experiments, RAD001 powder from LC
laboratories, Woburn, USA, was dissolved in 2 ml ethanoland diluted with 5% glucose solution in water to obtain 3
or 6 mg/ml. RAD001 was administered orally by gavage in
a volume of 0.2 ml; thus, 0.8 or 1.6 mg/rat or 2.5/5 mg/kg
BW was administered depending on treatment group. For
each administration, RAD001 was prepared freshly from
powder.
Radionuclides and peptides
DOTA0,Tyr3-octreotate was obtained from Mallinckrodt,
St. Louis, MO, USA, and 177LuCl3 was obtained from
IDB, Baarle-Nassau, the Netherlands. 177Lu-DOTATATE
was prepared as described before [20], with a specific activ-
ity of 100 MBq/2.75 μg peptide, and injected iv via the tail
vein under anesthesia. Labeling of 111In-DTPA-octreotide
(OctreoScan, Covidien, Petten, the Netherlands) in a spe-
cific activity of 30 MBq/0.5 μg DTPA-octreotide was per-
formed as described previously [21].
SPECT/CT scanning
Forty-eight hours after injection of 177Lu-DOTATATE,
helical single-photon emission computed tomography/
computed tomography (SPECT/CT) scanning of the
tumor region was performed with the four-headed
NanoSPECT/CT system (BioScan, Washington DC,
USA). Multi-pinhole rat collimators with nine pinholes
(diameter 2.5 mm) per head were used: 24 projections,
90 s per projection, were applied. SPECT scans were
reconstructed iteratively on a 256 × 256 matrix, using
HiSPECT NG software (Scivis GmbH, Göttingen Germany)
and ordered subset expectation maximization (OSEM).
The total amount of radioactivity (MBq) in the tumor was
quantified by drawing a sufficiently large volume of inter-
est (VOI) around the tumor using InVivoScope software
(IVS, Bioscan, Washington DC, USA). To achieve accurate
quantification, the camera was calibrated by scanning a
20-ml polypropylene tube rat phantom filled with a known
amount of 177Lu activity. The in vivo tumor volume was
assessed by setting the lower threshold to 90% of the
maximum voxel intensity of the tumor using the IRW
program (Siemens, Erlangen, Germany). Before euthan-
asia, a whole-body SPECT/CT scan of rats was acquired
24 h after intravenous injection of 111In-DTPA-octreotide
(50 MBq 111In/0.5 μg DTPA-octreotide) to detect CA20948
metastases. During scanning, the rat body temperature
was maintained using a heated bed.
In vitro autoradiography
Autoradiography was performed on primary tumors as
well as metastases. Frozen sections of 10 μm (Cryo-Star
HM 560 M; Microm, Walldorf, Germany) were mounted
on Superfrost plus slides (Menzel, Braunschweig, Germany)
and incubated with 10−10 M 111In-DTPA-octreotide with
and without an excess (10−6 M) of unlabeled octreotide.
Adjacent sections were used for hematoxylin/eosin
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imaging screens (Packard Instruments Co., Meriden,
USA) in X-ray cassettes. After a 48-h exposure, screens
were read by a Cyclone phosphor imager and analyzed
using OptiQuant 03.00 (PerkinElmer, Groningen, the
Netherlands).Statistics
Prism software version 5.0 (Graph Pad) was used to
analyze tumor growth and determine statistical signifi-
cance between groups. An unpaired T test was used for
statistical analysis of tumor uptake (Figure 1). Results
are given as mean ± SD. A log rank test was performed
for curve comparison in Figure 2A,B. Body weight data
in Figure 2C are expressed as mean values.Experimental design
An overview of the different research questions (A to E)
and treatment groups in all studies (1 to 3) is given in
Table 1 and described below.(A) Potential synergistic effect of RAD001 in combination
with 177Lu-DOTATATE
To study whether RAD001 has an additional anti-tumor
effect on 177Lu-DOTATATE, six different study groups
were included with six to seven rats per group. Besides
the control group and the RAD001-only therapy groups
(5 mg/kg twice a week for 4.5 weeks), two groups received
177Lu-DOTATATE as a single therapy in different doses
(125 or 275 MBq), and two groups received the same
doses of 177Lu-DOTATATE combined with RAD001 treat-
ment (5 mg/kg twice a week for 4.5 weeks starting 3 days
prior to PRRT) [11]. Rats were euthanized when tumor
size exceeded 4 cm3.Figure 1 Tumor concentration and quantification of sst2 expression. (
DOTATATE-only (light grey bar) and groups receiving 177Lu-DOTATATE 4 d
of sst2 expression in primary tumors and metastases based on in vitro auto
or 5 mg/kg; DLU, digital light unit.(B) Prolonged follow-up of potential development of distant
metastasis in all groups after surgical resection of the
primary tumor
Six additional groups of rats were included in the next
study with seven to eight rats in each group. To enable
prolonged follow-up, in this experiment, primary tumors
were surgically removed when >4 cm3. This enabled lon-
ger follow-up to study the development of metastases in
relation to the combination of 177Lu-DOTATATE and
RAD001 or RAD001-only. RAD001 (2.5 or 5.0 mg/kg)
was administered twice weekly for 4.5 weeks, either
alone or 3 days prior to 125 MBq 177Lu-DOTATATE.
(C) Influence of RAD001 on tumor uptake of
177Lu-DOTATATE
177Lu-DOTATATE uptake in tumors was quantified
based on SPECT/CT scans acquired 48 h after administra-
tion of 177Lu-DOTATATE in experiments 1 and 2 to
examine if previous RAD001 treatment results in reduced
177Lu retention in CA20948 tumors.
(D) Effects of prolonged RAD001 treatment
Five groups of eight rats were included. RAD001
(5 mg/kg) therapy was started 4 days after 125 MBq
177Lu-DOTATATE. RAD001 was administered twice a
week and continued for either 4.5 or 12 weeks. Surgical
resection was performed if tumors reached a volume of
6 cm3.
(E) Effects of PRRT re-treatment on metastases
If rats in experiment 3 showed lethargy or a >10% body
weight loss, SPECT/CT was performed using 111In-
DTPA-octreotide. If metastases could be discriminated,
400 MBq/10.8 μg 177Lu-DOTATATE PRRT was given.
Twenty-four hours after 177Lu-DOTATATE injections,
SPECT/CT was performed to image 177Lu-DOTATATEA) Tumor concentration of 177Lu-DOTATATE in rats receiving 177Lu-
ays after RAD001 therapy was started (dark grey bar). (B) Quantification
radiography. 177Lu-TATE, 177Lu-DOTA0,Tyr3-octreotate; RAD, RAD001 2.5
Figure 2 Graphs showing percentage of rats having primary tumors and metastases, and mean body weight of animals. (A) Percentage
of (LEW/SsNHsd Lewis) rats with primary tumors reaching the maximum size of >6 cm3 that underwent surgery afterwards to remove the tumor.
The control group received saline. RAD001 therapy started at day 4 (5 mg/kg administered twice weekly). 177Lu-DOTATATE (125 MBq) was
administered at day 1. (B) Percentage of (LEW/SsNHsd Lewis) rats developing metastases in each group. (C) Mean body weight of animals in the
control group (black line) and of the rats treated with either RAD001 or a combination of RAD001 and 177Lu-DOTATATE that did not develop
metastases (blue line) versus the body weight of rats treated with RAD001 or a combination of RAD001 and 177Lu-DOTATATE that developed
metastases (red line).
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by follow-up of body weight and 111In-DTPA-octreotide
SPECT/CT when ongoing decrease in body weight was
registered.
Results
(A) Potential synergistic effect of RAD001 in combination
with 177Lu-DOTATATE
In experiment 1, treatment with RAD001-only did not
result in any complete or partial anti-tumor responses,
defined as follows: partial response (PR), which is >50%
reduction of tumor volume, but no complete response
(CR), which is 100% reduction of tumor volume(Table 2). Groups treated with 177Lu-DOTATATE-only
showed 57% CR after 125 MBq 177Lu-DOTATATE and
71% after 275 MBq 177Lu-DOTATATE. Combination of
177Lu-DOTATATE and RAD001, however, resulted in
only 29% CR after 125 MBq 177Lu-DOTATATE +
RAD001 and 14% after 275 MBq 177Lu-DOTATATE +
RAD001. So, in contrast to our hypothesis, no additive
effect with regard to tumor response could be achieved
by combining RAD001 and 177Lu-DOTATATE. More-
over, unexpectedly, all rats treated with the combination
of RAD001 and 177Lu-DOTATATE and not showing
CR eventually developed metastases as was reported
earlier [11].
Table 1 Overview of the research questions and setup of the subsequent studies




(A) Potential synergistic effect of RAD001 in
combination with 177Lu-TATE (LEW/HanHsd)
1 Control 7 - Placebo
RAD only 6 - 5.0 mg/kg, 4.5 w
177Lu-TATE low dose 7 125 Placebo
177Lu-TATE high dose 7 275 Placebo
RAD + 177Lu-TATE low dose 7 125 5.0 mg/kg, 4.5 w
RAD + 177Lu-TATE high dose 7 275 5.0 mg/kg, 4.5 w
(B) Prolonged follow-up of potential development
of distant metastasis (LEW/HanHsd)
2 Control 8 - Placebo
Low-dose RAD 8 - 2.5 mg/kg, 4.5 w
High-dose RAD 8 - 5.0 mg/kg, 4.5 w
177Lu-TATE 7 125 Placebo
177Lu-TATE + low-dose RAD 8 125 2.5 mg/kg, 4.5 w
177Lu-TATE + high-dose RAD 7 125 5.0 mg/kg, 4.5 w
(C) Influence of RAD001 on tumor uptake of
177Lu-DOTATATE (LEW/HanHsd)
1 + 2 177Lu-TATE 21 125 or 275 Placebo
RAD + 177Lu-TATE 29 125 or 275 2.5 mg/kg or 5.0 mg/kg,
4.5 w
(D) Effects of prolonged RAD001 treatment
(LEW/SsNHsd)
3 Control 8 - Placebo
RAD 8 - 5.0 mg/kg, 4.5 w
177Lu-TATE + RAD 8 125 5.0 mg/kg, 4.5 w
RAD prolonged treatment 8 - 5.0 mg/kg, 12 w
177Lu-TATE + RAD prolonged
treatment
8 125 5.0 mg/kg, 12 w
(E) Effects of PRRT on growth of metastases
(LEW/SsNHsd)
3 High-dose 177Lu-TATE after diagnosis
of metastases
7 400 -
177Lu-TATE, 177Lu-DOTA0,Tyr3-octreotate; RAD, RAD001; PRRT, peptide receptor radionuclide therapy; w, weeks.
Bison et al. EJNMMI Research 2014, 4:21 Page 6 of 10
http://www.ejnmmires.com/content/4/1/21(B) Prolonged follow-up of potential development of
distant metastasis in all groups after surgical resection of
the primary tumor
Following prolonged monitoring after primary tumor
removal, the majority (77%) of rats treated with RAD001
(either 5.0 or 2.5 mg/kg) developed metastases that re-
sulted in mean body weight loss at around 43 days after
start of treatment. For these two doses, no dose depend-
ence of RAD001 was found (Table 2).
(C) Influence of RAD001 on tumor uptake of
177Lu-DOTATATE
The 177Lu tumor uptake in 177Lu-DOTATATE-only-
treated rats was 1.51 ± 0.07 kBq/mm3, while this was
1.42 ± 0.07 kBq/mm3 in rats pretreated with RAD001;
no significant different values were found between the
groups (p = 0.50, Figure 1A).
(D) Effects of prolonged RAD001 treatment
In contrast to previous experiments, 50% of the rats in the
control group showed a CR. The rats from the combin-
ation groups (177Lu-DOTATATE + RAD001 for 4.5 weeks
and 177Lu-DOTATATE + RAD001 for 12 weeks) showed a
CR in 87.5% and 75% (not significantly different; p = 0.63)of the animals, respectively, in comparison to only 12.5%
of rats in both RAD001-only therapy groups. Within these
two RAD001-only groups, there was no significant differ-
ence regarding both the number of animals that needed
surgery as well as the time until surgery.
With regard to development of metastases, at day 150
post start of treatment (p.t.), no metastases were detected
in untreated rats (Figure 2B). Also, the time of appearance
of the metastases in the combination group was later:
61 d p.t. vs. 91 p.t., respectively.
Monitoring the body weight of rats revealed the effects
of treatment and the development of metastases. Rats
in the control group showed a normal gain in body
weight over time (Figure 2C). Rats treated with 177Lu-
DOTATATE + RAD001 or RAD001-only not develop-
ing metastases also showed gain in body weight over
time, although at a slower rate. However, the mean body
weight of rats developing metastases stabilized as a result
of their poor condition.
(E) Effects of PRRT on growth of metastases
Although SPECT/CT confirmed significant uptake of
177Lu-DOTATATE in metastases (Figure 3), in only two
of the seven rats, there was CR after re-treatment with
Table 2 Overview of tumor responses
Experiment Group CR (%) PR (%) Rats with metastases (%) n
1 Controla 0 0 0 7
RAD 5 mg/kga 0 0 0 6
177Lu-TATE 125 MBq 57 29 0 7
177Lu-TATE 278 MBq 71 29 0 7
RAD 5 mg/kg + 177Lu-TATE 125 MBq 29 57 71 7
RAD 5 mg/kg + 177Lu-TATE 278 MBq 14 57 86 7
2 Controlb 0 0 0 8
RAD 5.0 mg/kgb 0 13 75 8
RAD 2.5 mg/kgb 13 0 63 8
177Lu-TATE 125 MBqb 43 57 0 7
177Lu-TATE 125 MBq + RAD 5.0 mg/kgb 0 63 88 8
177Lu-TATE 125 MBq + RAD 2.5 mg/kgb 14 43 86 7
3 Controlb 50 0 0 8
RAD 4.5 weeksb 12.5 12.5 37.5 8
RAD 12 weeksb 12.5 25 50 8
177Lu-TATE 125 MBq + RAD 4.5 weeksb 87.5 12.5 12.5 8
177Lu-TATE 125 MBq + RAD 12 weeksb 75 25 25 8
aRats did not survive until 42 to 146 days post start of treatment (p.t.), the time frame in which metastases became apparent in the other groups, because rats
had to be euthanized when primary tumor size was >4 to 6 cm3. bPrimary tumors were surgically removed when tumor size was >4 to 6 cm3. CR, complete
response (100% reduction of tumor size); PR, partial response (>50% reduction of tumor volume but no CR); n, number of animals/group; 177Lu-TATE, 177Lu-DOTA0,
Tyr3-octreotate; RAD, RAD001.
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of the non-responsive rats after detection and treatment
of the metastases varied between 8 and 37 days, with an
average of 27 days. One rat with CR recovered from a
liver metastasis that was clearly visualized after adminis-
tration of 177Lu-DOTATATE. Eight days later, there was
no sign of this lesion as shown in the 111In-octreotide
scan, which was confirmed after dissection. On the other
hand, a rat suffering from lung metastases did not respond
to 177Lu-DOTATATE. Eight days after re-treatment,
further loss in body weight was measured and the 111In-
DTPA-octreotide SPECT/CT still showed extended lungFigure 3 Two representative sets of SPECT/CT scans of rats before and
represent a rat with liver metastasis; the lesion was not detectable anymore o
PRRT. The two images at the right represent a rat treated for lung metastases.
before euthanasia of the rat because of ongoing weight loss. LuM, lung metametastases, also found at autopsy. Determination of sst2
density on CA20948 primary tumors and metastases
using in vitro autoradiography revealed no significant
differences (Figure 1B).
Discussion
We previously reported on the disappointing results of
the combination of mTOR inhibitor RAD001 with
177Lu-DOTATATE PRRT in the CA20948 rat tumor
model. No hypothesized synergistic effect was found;
the combination treatment appeared even less effective
than 177Lu-DOTATATE-only. This observation cannotafter re-treatment with 177Lu-DOTATATE. The two images at the left
n the scan with 111In-DTPA-octreotide made 8 days after 177Lu-DOTATATE
On the right, scan after injection of 111In-DTPA-octreotide was made
stasis; LiM, liver metastases; Kd, kidney.
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the subcutaneous CA20948 tumors after RAD001 treat-
ment, as we demonstrated here (Figure 1A).
Even more striking was the fact that the majority of
RAD001-treated animals developed tumor metastasis to
lymph nodes, liver, and/or lung. RAD001 initially has
been introduced as an immunosuppressant to protect
patients from rejecting allografts after organ transplant-
ation [22]. In 2005, Law et al. [23] reviewed the im-
munosuppressive effects of RAD001 in relation to its
anti-tumor effects and discussed immune suppression by
RAD001 to be tumor growth accentuating. Therefore,
the application of RAD001 as an anti-tumor agent should
be monitored carefully in the clinic, but to the best of our
knowledge as yet, no tumor accentuating effects in pa-
tients have been reported. Recently, after the publication
of our priority report on our first findings, RAD001 has
received FDA approval for the treatment of advanced
NETs and is commonly used in clinical practice nowadays.
Although we must consider the fact that RAD001 is used
in patients with already advanced (metastasized) disease,
so far, no reports on accelerated metastasis in patients re-
lated to RAD001 treatment have been published. We earl-
ier hypothesized multiple reasons for the occurrence of
metastases: the twice-weekly dose regimen instead of daily
dosing as is applied in clinical therapy, effects of RAD001
on the immune system and/or tumor microenvironment,
or the discontinuation of RAD001 treatment at 4.5 weeks
after start of treatment. In the current studies, we com-
pared 4.5 weeks of RAD001 treatment with 12 weeks of
twice-weekly RAD001 treatment. This prolonged RAD001
treatment (with or without 177Lu-DOTATATE therapy)
did not reduce the number of rats developing metastases,
and in addition, no delay in the occurrence of metastasis
was seen. In fact, comparison of the 4.5-week RAD001
groups versus 12-week RAD001 groups showed a higher
percentage of rats developing metastasis in the 12-week
RAD001 groups than in the 4.5-week RAD001 groups,
namely, 38% vs. 25% (p = 0.45). The average time until de-
tection of metastases was also not significantly different
between groups receiving RAD001 for 4.5 weeks (82 days
p.t.) versus 12 weeks (78 day p.t.). Moreover, in 67% of the
rats developing metastases in the 12-week treatment
groups, metastases were diagnosed while rats were still
receiving RAD001. Therefore, it is unlikely that the oc-
currence of metastases is due to cessation of RAD001
administration. Potentially, the twice-weekly adminis-
tration could lead to a repetitive on-off effect on the
mTOR pathway with repetitive upregulation/rebound
effects of the mTOR pathway with varying plasma con-
centration levels of RAD001 in a twice-weekly dose
regimen [24]. In future experiments, a daily RAD001
dose regimen will have to be compared to the twice-
weekly dose regimen as was used in the current studies.Compared to a treatment with RAD001-only, less ani-
mals receiving a combination of 177Lu-DOTATATE and
RAD001 developed metastases, and mean time to diag-
nosis for those metastases was 30 days later compared
to the rats receiving RAD001-only. Results from the
combination therapy groups with 177Lu-DOTATATE
administered 4 days before RAD001 therapy suggested
that 177Lu-DOTATATE administered prior to RAD001
therapy reduced both incidence and time of onset of
metastases in comparison to the reverse order combin-
ation. When 177Lu-DOTATATE was administered 4 days
after RAD001 therapy, however, there was no reduction
in the percentage of rats developing metastases in the
combination therapy groups, indicating that rats with
(some) tumor reduction already induced by PRRT were
less likely to develop metastases than rats not treated
with PRRT. This is in agreement with the fact that animals
that showed CRs after PRRT or PRRT plus RAD001 did
not develop metastases during follow-up.
In studies 1 and 2, we used a syngeneic tumor model
in rats with an uncompromised immune system. A sig-
nificant role for T lymphocytes in the immune response
to tumors after or during ionizing radiation therapy has
been described, the latter resulting in upregulation of
tumor-specific antigens [25-29]. As immune suppres-
sion by RAD001 has been proven to be mainly due to
suppression of T lymphocyte activation and prolifera-
tion [30,31], in our opinion, immune suppression by
RAD001 is a likely explanation for reduced tumor
response to PRRT in combination with RAD001 as
observed in our study. In studies 1 and 2, LEW/HanHsd
rats were used, whereas in study 3, the LEW/SsNHsd
substrain was used, providing the opportunity to test
the hypothesis mentioned above. In this substrain, the
immune system is more active compared to the HanHsd
strain and shows an enhanced (auto)-immune response
[13-17]. In these rats, 50% of tumors in the control
group went into spontaneous regression after reaching
an average tumor volume of ≈ 3 cm3, probably due to an
immune response against the growing tumor. In such
rats treated with RAD001 (4.5 or 12 weeks), only 12.5%
of the tumors went into regression. In a mouse model
on rejection of an allogeneic subcutaneous tumor as
created by Hammond-McKribben et al. [22], another
mTOR inhibitor, the rapamycin derivate SDZ RAD, was
used to prevent rejection of allogeneic tumors. So,
immune suppression by RAD001 might have caused
the reduced tumor response in our study with 177Lu-
DOTATATE administered after RAD001 as well.
Contrary to our results, a combination of ionizing radi-
ation (IR) with rapamycin has been proven to be more
effective than IR-only in preclinical studies [10,32,33].
These studies however have been performed in xenograft
models using immunodeficient mice lacking T cells.
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liferation rate caused by a G1 arrest could also be an
explanation for the reduced tumor response to 177Lu-
DOTATATE in rats treated with the combination of
RAD001 and 177Lu-DOTATATE. RAD001 treatment
has been shown to cause a G1 arrest, as mTOR is being
linked to phosphatidylinositol 3-kinase (PI3K) path-
ways [34]. Within 24 h after RAD001 administration, a
significant increase of cells in G1 phase has been de-
scribed [35,36]. As cells with a long cycling time, in-
cluding NET cells, have a peak of radioresistance
during early G1 phase [37], tumor cells may have been
less sensitive to 177Lu-DOTATATE when administered
4 days after the start of RAD001 treatment. Since clin-
ical trials combining RAD001 and PRRT are being per-
formed [38], in our opinion, the decreased anti-tumor
response in our study when RAD001 was administered
prior to 177Lu-TATE is rather relevant. Also, in a clin-
ical situation, the combination of both therapies might
be less effective compared to just PRRT.
For re-treatment of the rats with metastases, we used
a dose of 400 MBq 177Lu-DOTATATE, which is remark-
ably higher compared to the initial 125 or 275 MBq
treatment doses. Still, only two out of seven rats with
metastases were cured, suggesting metastases in our
model to be more resistant to PRRT compared to the
primary tumor. As it is quite complex to study responses
of metastases in a preclinical model, there have not been
many preclinical studies on therapies in metastatic
models. However, to be able to get more solid informa-
tion on sensitivity of metastases to PRRT in a preclinical
model, certainly more studies in different models are ne-
cessary. The current CA20948 metastatic tumor model
after RAD001 treatment could be a more realistic metas-
tasis model for future experiments compared to often-
applied metastasis tumor models in which tumor cell
suspensions are injected intravenously.
Conclusions
Results described here confirmed and provided more in-
formation on development of metastasis after RAD001
treatment in our in vivo rat tumor model. The impaired
tumor response to the combination of RAD001 and
177Lu-DOTATATE in comparison with that after 177Lu-
DOTATATE-only could not be attributed to a reduced
tumor uptake of 177Lu-DOTATATE in rats after RAD001
treatment. Moreover, the occurrence of metastases could
not be attributed to the sudden cessation of RAD001
treatment, as we observed treatment for 12 weeks did not
result in a lower metastasis rate compared to treatment
for 4.5 weeks. Immune suppression by RAD001 could be a
good explanation for reduced tumor response after
RAD001 as well as for development of metastasis. More
studies in different tumor models are needed now toprovide proof and give detailed information on the
translational value of these findings to the clinic.
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